2014
An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone
Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. Journal Of Substance Use And Addiction Treatment 2014, 47: 35-40. PMID: 24674234, PMCID: PMC4042403, DOI: 10.1016/j.jsat.2014.02.008.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialXR-NTXGamma-glutamyl transferaseAlanine aminotransferaseMental illnessAspartate aminotransferaseRandomized placebo-controlled trialMonthly injectable formulationXR-NTX armExtended-release naltrexoneHepatic enzyme elevationHepatic enzyme levelsRelease naltrexoneAntiretroviral therapyHCV infectionBaseline characteristicsHepatic transaminasesEnzyme elevationPsychiatric medicationsHepatotoxicity concernsGlutamyl transferaseAlcohol dependenceOpioidsHIVNaltrexone
2010
HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners
Springer SA, Azar MM, Altice FL. HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. The American Journal Of Drug And Alcohol Abuse 2010, 37: 12-21. PMID: 21171933, PMCID: PMC3070290, DOI: 10.3109/00952990.2010.540280.BooksConceptsAlcohol use disorderHIV treatment outcomesTreatment outcomesAlcohol dependencePoor HIV treatment outcomesRole of pharmacotherapyRelationship of HIVHIV risk behaviorsBetter treatment outcomesEvidence-based treatmentsAntiretroviral therapySignificant morbidityTherapeutic optionsPoor adherenceAlcohol abuseHIVUse disordersHIV cycleCommunity settingsRisk behaviorsAlcohol usePrimary articlesImproved treatmentVulnerable populationsNaltrexone